Prevents rejection in renal homotransplantation. ANDA 75568, held by Rising. Azathioprine.
As of Nov 16, 2026, ANDA 75568 (Azathioprine), held by Rising, was first approved by FDA on Dec 13, 1999, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: Azathioprine tablets are
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azathioprine50MG · tablet;oral | Azathioprine | Rx |
| Jul 16, 2026 | Supplement 31Labeling · Standard review | Approved | None posted |
| Apr 23, 2019 | Supplement 27Labeling · Standard review | Approved | None posted |
| May 29, 2015 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 23, 2011 | Supplement 15Labeling | Approved | None posted |
| Jun 28, 2008 | Supplement 13Labeling | Approved | None posted |
| Mar 6, 2007 | Supplement 10Labeling | Approved | None posted |
| Nov 19, 2003 | Supplement 7Labeling | Approved | None posted |
| Jun 4, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Sep 17, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Feb 21, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Feb 21, 2001 | Supplement 2Labeling | Approved | None posted |
| Dec 13, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters